SCHEMBL12237494

SCHEMBL12237494

O=C(O)c1cc(-c2ccc(-c3ccccc3)cc2)nc2ccc(Br)cc12

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.75
DHODH Q02127 4/20 0.72
EPRS1 P07814 3/20 0.71
HSD17B10 Q99714 4/20 0.70
HIF1A Q16665 2/20 0.70
TP53 P04637 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2C19 P33261 1/20 0.70
KDM4E B2RXH2 4/20 0.66
ALDH1A1 P00352 3/20 0.66
LMNA P02545 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
PDE10A Q9Y233 1/20 0.66
MEN1 O00255 3/20 0.64
PPARG P37231 3/20 0.64
KMT2A Q03164 3/20 0.64
NCOR2 Q9Y618 3/20 0.64
POLB P06746 2/20 0.64
GAA P10253 1/20 0.64
MC4R P32245 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899098 0.97 RXFP1 (0.79) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL117430 0.93 EPRS1 (0.79) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL12237496 0.92 RXFP1 (0.67) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL5530291 0.89 EPRS1 (0.85) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL5838639 0.87 DHODH (0.74) RXFP1DHODHEPRS1HSD17B10KDM4E
SCHEMBL18320549 0.87 DHODH (0.76) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL1898124 0.87 KDM4E (0.72) RXFP1DHODHEPRS1HSD17B10HIF1A
SCHEMBL7814193 0.86 GAA (0.71) RXFP1DHODHEPRS1HSD17B10KDM4E
SCHEMBL29788463 0.85 DHODH (0.80) DHODHEPRS1TP53KDM4ELMNA
SCHEMBL116022 0.85 DHODH (0.80) DHODHEPRS1TP53KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710079-B2 Quinoline compounds and their use for treating viral infection NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2014-04-29 US disclosed
US-8710079-B2 Quinoline compounds and their use for treating viral infection NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2014-04-29 US disclosed
US-20110263620-A1 QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2011-10-27 US disclosed
US-20110263620-A1 QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263620-A1 QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION RECQL, IFNG, NQO2 RXFP1 789/4885DHODH 1914/4885EPRS1 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.